|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2002-3-4
|
|
pubmed:abstractText |
The endogenous viral superantigen 7 in DBA/2 mice serves as a target antigen on syngeneic ESb-MP lymphoma cells for allogeneic graft-vs-leukaemia reactive cells. Allogeneic viral superantigen 7 reactive Vbeta6+ T cells are able to transfer graft-vs-leukaemia reactivity and to kill specifically viral superantigen 7+ ESb-MP tumour cells in vitro. Here we elucidate the mechanism of this superantigen specific cell lysis. Already 10 min after co-incubation with in vitro stimulated Vbeta6+ T cells, viral superantigen 7+ ESb-MP tumour cells show an apoptotic phenotype (Annexin V-positivity, DNA-fragmentation). This extremely rapid type of cell death is not mediated by the death inducing ligands CD95L, TRAIL and TNF but by perforin and granzyme B. Surprisingly, neither mitochondria nor any of the known caspases appear to be involved in this type of tumour cell killing. In contrast, nitric oxide, released by activated macrophages and endothelial cells, induces in the same tumour cells another type of apoptosis which is much slower and involves mitochondria and caspase activation. A synergistic effect between the two different effector mechanisms of superantigen reactive donor cytotoxic T lymphocytes and nitric oxide releasing host macrophages and endothelial cells might explain the effective immune rejection of even advanced metastasised cancer in this graft-vs-leukaemia animal model.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/11875749-10090945,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11875749-10360966,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11875749-10367904,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11875749-10367905,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11875749-10510346,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11875749-10733506,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11875749-10802706,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11875749-10802713,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11875749-10815924,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11875749-10894162,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11875749-10925364,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11875749-11081635,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11875749-1311018,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11875749-1330577,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11875749-1710925,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11875749-2569027,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11875749-2787530,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11875749-6491605,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11875749-7518614,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11875749-7530335,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11875749-7566090,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11875749-7632930,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11875749-7882166,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11875749-8068938,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11875749-8777713,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11875749-8885990,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11875749-9047242,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11875749-9065443,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11875749-9247146,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11875749-9311998,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11875749-9446633,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11875749-9586635,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11875749-9670928,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11875749-9767460,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11875749-9820488,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11875749-9865926,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11875749-9916752,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11875749-9917913
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0007-0920
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2002 Cancer Research UK
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
4
|
|
pubmed:volume |
86
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
828-36
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:11875749-Animals,
pubmed-meshheading:11875749-Apoptosis,
pubmed-meshheading:11875749-Caspases,
pubmed-meshheading:11875749-Granzymes,
pubmed-meshheading:11875749-Leukemia, T-Cell,
pubmed-meshheading:11875749-Ligands,
pubmed-meshheading:11875749-Lymphoma, T-Cell,
pubmed-meshheading:11875749-Membrane Glycoproteins,
pubmed-meshheading:11875749-Mice,
pubmed-meshheading:11875749-Perforin,
pubmed-meshheading:11875749-Pore Forming Cytotoxic Proteins,
pubmed-meshheading:11875749-Serine Endopeptidases,
pubmed-meshheading:11875749-Superantigens,
pubmed-meshheading:11875749-T-Lymphocytes,
pubmed-meshheading:11875749-Tumor Cells, Cultured
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Superantigen reactive Vbeta6+ T cells induce perforin/granzyme B mediated caspase-independent apoptosis in tumour cells.
|
|
pubmed:affiliation |
Division of Cellular Immunology, G0100, Tumorimmunology Program, German Cancer Research Center, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
